myogenin (؊/؊) mice display severe skeletal muscle defects despite expressing normal levels of MyoD. The failure of MyoD to compensate for myogenin could be explained by distinctions in protein function or by differences in patterns of gene expression. To distinguish between these two possibilities, we compared the abilities of constitutively expressed myogenin and MyoD to support muscle differentiation in embryoid bodies made from myogenin (؊/؊) ES cells. Differentiated embryoid bodies from wild-type embryonic stem (ES) cells made extensive skeletal muscle, but embryoid bodies from myogenin (؊/؊) ES cells had greatly attenuated muscle-forming capacity. The inability of myogenin (؊/؊) ES cells to generate muscle was independent of endogenous MyoD expression. Skeletal muscle was restored in myogenin (؊/؊) ES cells by constitutive expression of myogenin. In contrast, constitutive expression of MyoD resulted in only marginal enhancement of skeletal muscle, although myocyte numbers greatly increased. The results indicated that constitutive expression of MyoD led to enhanced myogenic commitment of myogenin (؊/؊) cells but also indicated that committed cells were impaired in their ability to form muscle sheets without myogenin. Thus, despite their relatedness, myogenin's role in muscle formation is distinct from that of MyoD, and the distinction cannot be explained merely by differences in their expression properties.
INTRODUCTION
Myogenin is a myogenic bHLH transcription factor that plays essential roles in skeletal muscle differentiation during embryogenesis (for recent reviews, see Arnold and Braun, 2000; Sabourin and Rudnicki, 2000) . Knockout mice lacking the myogenin gene die at birth due to severe skeletal muscle deficiency (Hasty et al., 1993; Nabeshima et al., 1993) . In these mice, committed myoblasts migrate to their proper locations but most do not fuse to form myofibers, indicating that myogenin is required for myoblast fusion and differentiation but not for commitment to the myogenic lineage. Notably, MyoD and myf5 are ex-pressed at normal levels in myogenin-knockout mice, implying that myogenin's function in skeletal muscle differentiation cannot be replaced by these closely related bHLH transcription factors. Despite the importance of the myogenic regulatory factors, surprisingly little is known about why myogenin activates genes in vivo that cannot be activated by MyoD and myf5.
In contrast to myogenin, MyoD and myf5 function in myogenic commitment, implying that myogenin lies downstream of MyoD and myf5 in a genetic regulatory pathway (reviewed in Yun and Wold, 1996; Arnold and Braun, 2000; Sabourin and Rudnicki, 2000) . However, this simple view has been recently challenged and found to be inadequate. As well as having a role in myoblast commitment, MyoD also has a role in myoblast differentiation and that role is redundant with that of MRF4, the fourth member of the myogenic regulatory protein family (Rawls et al., 1998) . The redundant functions of MRF4 and MyoD appear not to overlap with those of myogenin (Valdez et al., 2000) . Thus, knockout mice reveal roles for MyoD at two distinct steps in myogenesis, commitment and differentiation, while myf5 appears to play a role solely in commitment, and myogenin and MRF4 play roles solely in differentiation.
The mechanistic basis for the selective function of myogenin and the other myogenic regulators remains elusive. The high degree of sequence divergence among the four factors outside of the bHLH region implies that each factor has evolved a specialized role in mammalian myogenesis. Nevertheless, the spatial, temporal, and quantitative patterns of expression of these factors are not identical, suggesting that the transcription regulatory regions controlling gene expression are also important in the requirements of each factor.
One group of investigators has attempted to directly distinguish between function and regulation of the myogenic regulatory factors in vivo. Wang and co-workers (1996) investigated whether myogenin could functionally replace myf5 by inserting myogenin into the myf5 locus. This allele fully rescued the rib defect observed in myf5 (Ϫ/Ϫ) mice, suggesting that myogenin can replace myf5's role in this process (Wang et al., 1996) . However, recent evidence indicates that loss of myf5 is not the true cause of the rib defect, which makes the suggested functional relationship between myogenin and myf5 less clear (Kaul et al., 2000) . Moreover, although myogenin inserted into the myf5 locus in a MyoD (Ϫ/Ϫ) background replaced myf5's function in myoblast commitment, it did not rescue skeletal muscle differentiation when this allele was placed into a myogenin-null background (Wang and Jaenisch, 1997) . Because myf5 expression precedes that of myogenin by 48 h in mouse embryos (Sassoon et al., 1989; Ott et al., 1991) , and because skeletal muscle formation is highly sensitive to myogenin levels (Vivian et al., 1999) , it is likely that insufficient amounts of myogenin were available at the required time to restore the muscle defect. These experiments indicate that changes in myogenin's temporal expression pattern can dramatically affect its ability to function as a muscle regulatory protein. However, the experiments did not reveal whether other myogenic regulatory bHLH proteins could replace myogenin if expressed under the same transcriptional control as myogenin.
Functional differences in non-bHLH regions between MyoD and myogenin have been reported by Gerber et al. (1997) using cultured 10T1/2 fibroblasts. Two regions in MyoD appear to be involved in remodeling repressed chromatin to mediate transcriptional activation of genes. These regions are not conserved in myogenin, and functional assays show that while MyoD can remodel chromatin, myogenin cannot. These results are consistent with the role of MyoD in early specification events and provide a possible molecular feature in MyoD that distinguishes it from myogenin.
We were interested in establishing the basis for myogenin's specific function in the differentiation of skeletal muscle. In particular, we wondered why MyoD cannot compensate for myogenin in myogenin (Ϫ/Ϫ) mice. Perhaps MyoD is capable of functionally replacing myogenin but the temporal and spatial expression patterns of MyoD are sufficiently different from those of myogenin so that critical levels of MyoD are not produced at the required time and place to mediate the response.
To prove that myogenin's essential role in myogenesis is due to functional specialization and not merely the regulation of its expression, a system is required in which myogenin can be removed and other myogenic bHLH factors added in its place. Several recent studies have made use of embryonic stem (ES) cells to investigate the function of the myogenic factors (Shani et al., 1992; Braun and Arnold, 1994; Weitzer et al., 1995; Dinsmore et al., 1996) . Upon removal of the growth factor LIF, ES cells can differentiate into skeletal, smooth, and cardiac muscle, with each type exhibiting a characteristic contracting pattern. When ES cells differentiate into skeletal muscle, the myogenic bHLH factors are expressed in the same temporal sequence as seen in vivo (Rohwedel et al., 1994) , implying that the myogenic program is faithfully recapitulated in the ES cell system. Both wild-type ES cells and ES cells lacking myf5 and other muscle genes have been used to investigate skeletal myogenesis. In our laboratory, ES cells have been generated from myogenin (Ϫ/Ϫ) mice (Myer et al., 1997) and exogenous genes can be introduced into them by conventional DNA electroporation methods. An advantage of ES cells is that multiple ES cell lines derived from a genetically identical parental line can be quickly tested for their muscle-forming properties without the complications associated with generating knock-in and transgenic mice.
In this report, we describe the features of an ES cell differentiation system in which myogenin (Ϫ/Ϫ) ES cells do not form muscle sheets lacking centralized nuclei while wild-type ES cells do. Introducing myogenin back into myogenin (Ϫ/Ϫ) ES cells by forced expression restored muscle sheet formation. In contrast, forced expression of MyoD did not lead to muscle sheets. Our results indicate that myogenin is functionally distinct from MyoD and that MyoD does not compensate for myogenin in myogeninknockout mice because of functional rather than regulatory differences.
MATERIALS AND METHODS

Growth and Differentiation of ES Cells
Wild-type ES cell lines AB1 and AB2.1 were provided by Allan Bradley, Baylor College of Medicine, and have been described previously (McMahon and Bradley, 1990; Soriano et al., 1991) . myogenin (ϩ/Ϫ) (No. 17) and myogenin (Ϫ/Ϫ) (No. 18 and 2C1) ES cell lines were described by Myer et al. (1997) . Proliferating ES cells were cultured on mitotically inactivated mouse embryonic fibroblast STO feeder cells in medium consisting of DMEM containing 10% fetal bovine serum (Hyclone, Cat. No. SH30070 or SH30071), 2 mM L-glutamine, 100 units/ml penicillin, 100 g/ml streptomycin, and 0.125 mM ␤-mercaptoethanol (Robertson, 1987) . Freshly thawed cells were passed at least one time, grown to confluence, and harvested for embryoid body differentiation using the methods of Weitzer et al. (1995) . The cells were diluted to 2 ϫ 10 4 cells/ml in differentiation medium [DMEM containing 15% fetal bovine serum from Sigma (Cat. No. F-2442, Lot 46H4648 or 69H84211), 2 mM L-glutamine, 50 units/ml penicillin, 50 g/ml streptomycin, 0.143 mM ␤-mercaptoethanol], from which 20-l hanging drops were made. After 5 days, 50 to 150 drops were pooled and plated onto a 0.1% gelatin-coated surface. Fresh differentiation medium was added periodically to the differentiating embryoid bodies when the indicator dye changed from red to yellow.
DNA Transfections and Detection of Gene Expression
The myogenin-expressing cDNA plasmid (pEMSVMyo8) was described by Edmondson and Olson (1989) . The MyoD-expressing cDNA plasmid (pEMC11s) was obtained from Andrew Lassar, Harvard Medical School (Davis et al., 1987) , and the hygromycinresistant plasmid (pgk-hygro) was obtained from Richard Behringer (M. D. Anderson Cancer Center; Shawlot et al., 1998) . Each cDNA plasmid was introduced into the 2C1 myogenin (Ϫ/Ϫ) ES cell line by electroporation along with the hygromycin-resistant plasmid. The myogenin-expressing plasmid was linearized with SalI, the MyoD-expressing plasmid with XbaI, and the hygromycin-resistant plasmid with HindIII. All three linearized plasmids were purified from residual protein by extraction with phenol/chloroform, precipitated in ethanol, and resuspended in 10 mM Tris-HCl, pH 8.0, and 10 mM EDTA prior to electroporation. myogenin (Ϫ/Ϫ) 2C1 ES cells were grown to confluence on STO feeder cells prior to being harvested for electroporation. Fresh medium was supplied to the confluent cells for 2 h before digestion with trypsin for 10 min. Approximately 4 ϫ 10 7 cells were washed three times with PBS and resuspended in 1 ml of PBS with 20 g of linearized cDNA plasmid mixed with 2 g of linearized hygromycin-resistance plasmid. A Bio-Rad gene pulser (Hercules) set at 0.23 kV was used to shock the cells; they were then plated onto nine 10-cm plates containing hygromycin-resistant mitotically inactivated STO cells (SNL-H; provided by Jim Martin, Texas A&M University; Shawlot et al., 1998) . Drug selection was begun 24 h later with 86 g/ml hygromycin B (Sigma, Cat. No. H3274).
Colonies appeared 10 to 14 days after selection and were picked and maintained under hygromycin B selection in 96-well plates. Approximately every third day, the colonies were trypsinized for 3 min. Clones that thrived under these conditions were passed to a 24-well plate with no hygromycin B. Once confluent, each colony was split among three wells of a 24-well plate. After confluency was reached, cells from 1 well were used for DNA isolation, cells from the second well for RNA isolation, and cells from the third were passed to 1 well of a 6-well plate. When these cells reached confluency, they were frozen and stored under liquid nitrogen until further use.
Clones carrying cDNA plasmids were identified by Southern hybridization analysis. The genomic DNA was digested with EcoRI before electrophoresis and blotting. The corresponding cDNA plasmids were digested with EcoRI, and cDNA inserts were isolated, radiolabeled, and used as probes for Southern hybridization.
Clones that contained integrated cDNA plasmid were analyzed for myogenin or MyoD expression by RT-PCR. RNA was isolated Asterisk indicates that the genotype is statistically significantly different from the wild-type genotype (P Յ 0.01). Note that the ordinate scale on A, B, and C varies to allow for all three data sets to be presented. from undifferentiated ES cells, and RT-PCR was performed as described below. The primers used to detect myogenin transcripts are shown in Table 1 . For detecting MyoD transcripts that were derived from the plasmid, the following primers were used: forward, 5Ј CAA ATA AAG CAA TAG CAT C 3Ј, and reverse, 5Ј GTT TGT CAC TTT CTG GAG 3Ј. The annealing temperature was 59°C.
Immunostaining
Fifty 5-day-old hanging drops containing embryoid bodies were pooled and dispersed among eight chambers of two-chamber glass slides (Fisher, ) coated with 0.1% gelatin. Embryoid bodies were differentiated for an additional 22 days unless otherwise noted and fixed in either acetone (myosin heavy chain staining) or 1% paraformaldehyde (MyoD staining) at 4°C. Fixed cells were immunostained using a HistoMouse-SP kit (Zymed). Antibodies for myosin heavy chain were A4.1025 supernatant at 1:2 dilution or MF20 ascites at 1:800 dilution, supplied from the Developmental Studies Hybridoma Bank (Johns Hopkins University and University of Iowa, Contract N01-HD-6-2915 from NICHD). For MyoD immunostaining, M-318 at 2.5 g/ml was used (Santa Cruz Biotechnology).
RNA Isolation and RT-PCR
One hundred fifty hanging drops were pooled after 5 days of culture and plated onto a 0.1% gelatin-coated 24-well plate. After an additional 22 days in culture, plates were examined for contracting skeletal muscle. Up to 5 wells of contracting muscle were harvested for RNA isolation using the TRI Reagent method (Molecular Research Center).
Three micrograms of RNA isolated from differentiated embryoid bodies or 1 g of RNA from wild-type mouse hindlimbs was reverse transcribed using Superscript II (Life Technologies). Two microliters of the RT product was used for PCR. Standard PCR conditions were employed with Roche Taq polymerase and Clontech Taqstart antibody. For MyoD, myf5, and MRF4, a 5-min "hot start" preceded 35 cycles of the following: 94°C for 30 s, 65°C for 30 s, and 72°C for 1 min. For myogenin, the annealing temperature was 62°C. The sequences of the primers used for each PCR are shown in Table 1 .
For competitive PCR, the above conditions were used with the addition of a known concentration of a shortened competitor plasmid template (Gilliland et al., 1990) . The myogenin competitor plasmid was generated by subcloning a 1.0-kb EcoRI fragment of a myogenin cDNA into the EcoRI site of pBluescript SK (Stratagene). To shorten the sequence between the two primer annealing sites, a 102-bp StuI fragment from the myogenin cDNA was deleted by digesting the subclone with StuI and ligating the resulting shortened plasmid. The MyoD competitor plasmid was generated by subcloning a MyoD cDNA into the EcoRI site of pBluescript SK in which the EcoO109I was destroyed. The subclone was digested with EcoO109I to remove an 88-bp EcoO109I fragment from the cDNA and the shortened cDNA was religated. The myogenin competitor plasmid was linearized with BamHI prior to use. Plasmid concentrations were determined by agarose gel electrophoresis using standard DNAs of known concentration. One-D multi (line) densitometry was performed on an Alphaimager 2200 system (Alpha Innotech Corp.) for quantifying the PCR products.
Morphological and Statistical Analyses
Embryoid bodies stained with myosin heavy chain antibodies were examined for the presence of positive-staining myocytes, short myotubes (less than or equal to 480 m), long myotubes (greater than 480 m), and muscle sheets lacking centralized nuclei. For morphological quantification, each sample, which represented pooled embryoid bodies from one chamber, was scored as positive or negative for the presence of any myocytes, myotubes, or muscle sheets. In addition, each chamber was scored on a density scale of 0 (none) to 4ϩ (most) to indicate the extent of myocyte, myotube, and muscle sheet density in a given sample. This subjective density scale was necessary because it was not possible to precisely count the number of myotubes and muscle sheets within a chamber since they were intermingled with one another.
For statistical analysis, each sample was given the value of its density score. The density scores for myocytes, short myotubes, long myotubes, or muscle sheets from each ES cell line were added and, together with the total number of samples, were analyzed by E. Neely Atkinson and L. B. Levy (M. D. Anderson Cancer Center) using ordinal logistic regression with the software package JMP from SAS. Pair-wise comparisons were performed between ES cell genotypes. The predictors were genotype, ES cell line (genotype), and time (genotype, ES cell line), where notation "A(B)" indicates that variable A is nested in variable B. If either ES cell line or time was not significant, that variable was then removed from the model. P values were computed using likelihood ratio statistics.
RESULTS
myogenin (؊/؊) ES Cells Are Ineffective in Skeletal Muscle Differentiation
myogenin-knockout mice make very little skeletal muscle, even though myoblasts appear to form normally (Hasty et al., 1993; Nabeshima et al., 1993; Venuti et al., 1995) . Surprisingly, when myogenin (Ϫ/Ϫ) myoblasts are isolated from embryos and induced to differentiate in vitro, they do so with the same efficiency as wild-type myoblasts (Nabeshima et al., 1993; Rawls et al., 1995) . Moreover, in chimeric mice created with myogenin (Ϫ/Ϫ) ES cells, myogenin (Ϫ/Ϫ) myoblasts participate efficiently in myofiber formation as long as sufficient numbers of wild-type myoblasts are present (Myer et al., 1997) . These results indicate that the extracellular environment strongly influences the differentiation capabilities of myogenin (Ϫ/Ϫ) myoblasts. Unfortunately, the ability to fuse and differentiate limits the usefulness of isolated myogenin (Ϫ/Ϫ) myoblasts as a tool to study muscle differentiation in vitro. To investigate myogenin's role in muscle differentiation more precisely, we sought to develop an in vitro system that would reflect the extracellular environment of myogenin (Ϫ/Ϫ) embryos and also mimic the skeletal muscle defects associated with the absence of myogenin.
myogenin (Ϫ/Ϫ) ES cells were cultured alongside myogenin (ϩ/Ϫ) ES cells or wild-type ES cells, and embryoid bodies generated from these ES cell lines were allowed to differentiate. In our hands, wild-type embryoid bodies produced contracting skeletal muscle 20 to 25 days after differentiation was induced. Each ES cell line was examined for the presence of myocytes, myotubes, and muscle sheets lacking centralized nuclei as determined by their morphological features and expression of myosin heavy chain. Myocytes were identified as myosin heavy chain-positive mononucleate cells that had rounded or spindle-shaped morphology (Fig. 1A) . Myosin heavy chain-expressing tubular structures with multiple centralized nuclei were designated myotubes (Fig. 1B) , and enlarged syncytial tubes or sheets in which nuclei were no longer apparent were defined as muscle sheets (Figs. 1C and 1D) . myogenin (Ϫ/Ϫ) ES cells produced myocytes and myotubes in numbers that were not statistically different from the numbers for wildtype or myogenin (ϩ/Ϫ) controls ( Figs. 2A and 2B) . These results were not unlike those observed in vivo, in which myogenin (Ϫ/Ϫ) embryos had appreciable levels of myosinand MyoD-positive mononucleate cells and poorly differentiated fibers (Hasty et al., 1993; Nabeshima et al., 1993; Venuti et al., 1995) .
In contrast to results for myocytes and myotubes, major differences were found in the number of muscle sheets when myogenin (Ϫ/Ϫ) ES cells were compared with wildtype or heterozygous ES cells ( Figs. 2C and 3C ). The percentage of samples, where a sample is defined as pooled embryoid bodies from a single immunostained chamber, from wild-type and myogenin (ϩ/Ϫ) ES cells that produced muscle sheets ranged from 15 to 28%, whereas less than 4% of the samples from myogenin (Ϫ/Ϫ) ES cells produced muscle sheets. Moreover, the myogenin (Ϫ/Ϫ) samples producing muscle sheets rarely had fiber density values greater than 1ϩ, whereas values of control samples ranged from 1ϩ to 4ϩ (Fig. 2C ). The differences between myogenin (Ϫ/Ϫ) and wild-type ES cells were highly significant (P Ͻ 0.0001) and were reproducible in multiple independent ES cell clones of each genotype. These results demonstrate that myogenin (Ϫ/Ϫ) ES cells closely resemble myogenin (Ϫ/Ϫ) embryos in their inability to form differentiated skeletal muscle.
Restoration of Muscle Sheets in myogenin (؊/؊) ES Cells by Constitutive Expression of Myogenin
To ensure that the absence of myogenin was directly responsible for the observed defects in skeletal muscle differentiation in myogenin (Ϫ/Ϫ) ES cells, we introduced exogenous myogenin into these ES cells under the control of the constitutive EMSV promoter. Two representative ES cell lines expressing myogenin were selected and induced to differentiate alongside the parental myogenin (Ϫ/Ϫ) ES cell lines and the wild-type and myogenin (ϩ/Ϫ) controls. The two myogenin-expressing ES cell lines produced muscle sheets at least as effectively as wild-type or heterozygous controls (Figs. 2C, 4A, and 4B) , whereas the parental line, which was transfected with only the hygromycin expression vector, did not differentiate into skeletal muscle sheets (Fig. 2C) .
Qualitative differences were observed between constitu-tively expressing myogenin ES cells and wild-type or heterozygous controls. Both myogenin-expressing lines formed a higher percentage of muscle sheets (29 to 38% compared with 15 to 28%; Fig. 2C ). In addition, samples from the myogenin-expressing ES cells tended to make larger muscle sheets (Figs. 4A and 4B) . This difference was reflected in lower muscle sheet density values for the myogeninexpressing lines (Fig. 2C) . The reason for qualitative differences in muscle sheet formation between endogenously and exogenously expressing myogenin ES cells is not known but might involve a lack of temporal or quantitative regulation in the constitutively expressing lines.
To determine the levels of myogenin that were expressed in the constitutive ES cell lines, we quantified myogenin transcripts using competitive RT-PCR (Gilliland et al., 1990) . One line expressed myogenin at levels equivalent to those of wild-type or heterozygous ES cells, while a second line expressed five times more myogenin transcript (Table  2) . Because no appreciable differences were observed in muscle sheet formation between the two constitutively expressing lines, these results indicated that myogenin could function efficiently in this differentiation system over a fivefold range of expression levels.
MyoD is expressed at normal levels in myogenin (Ϫ/Ϫ) embryos (Hasty et al., 1993; Rawls et al., 1995) . To determine the extent of MyoD expression in differentiated myogenin (Ϫ/Ϫ) embryoid bodies, we determined MyoD expression levels by competitive RT-PCR. One myogenin (Ϫ/Ϫ) ES cell line expressed MyoD at levels comparable to those of wild-type controls while two others expressed MyoD at 25% of controls, yet none of these lines was able to form differentiated muscle sheets (Table 2) . Although not conclusive, these results suggest that the presence of MyoD was not adequate for muscle sheet differentiation in myogenin (Ϫ/Ϫ) ES cells. This supports earlier in vivo analyses showing that endogenous expression of MyoD was insufficient to promote skeletal muscle differentiation in the absence of myogenin. In contrast, the two constitutively expressing myogenin lines had attenuated levels of MyoD transcript (Table 2) . One line expressed MyoD at only 17% of wild-type levels, while the other line had undetectable levels. The reason for the low levels of MyoD in these myogenin-expressing ES cells is unclear, but nonetheless low MyoD levels did not prevent robust muscle sheet formation in the presence of appropriate levels of myogenin.
Inability of Constitutive Expression of MyoD to Restore Muscle Sheet Formation in Differentiating myogenin (؊/؊) ES Cells
Because myogenin and MyoD have similar muscleinducing behavior in tissue culture cells, constitutive expression of MyoD in myogenin (Ϫ/Ϫ) ES cells should be a stringent test of functional redundancy between myogenin and MyoD. We therefore introduced MyoD into myogenin (Ϫ/Ϫ) ES cells under the control of the same EMSV pro- moter that we used for constitutive myogenin expression. Two MyoD-expressing lines were selected and induced to differentiate. Both lines showed the same characteristics; most importantly, they did not produce substantial quantities of muscle sheets (Fig. 4C) . The percentage of samples that produced muscle sheets was only slightly higher than for myogenin (Ϫ/Ϫ) ES cell lines, and these samples never had muscle sheet density values above 1ϩ (Fig. 2C) .
Although skeletal muscle sheet formation in the MyoDexpressing myogenin (Ϫ/Ϫ) ES cells was inefficient, we did observe a significant increase in the number of myocytes (P Ͻ 0.001; Fig. 2A ). This increase was reflected in the higher myocyte density values for individual samples of MyoD-expressing embryoid bodies ( Fig. 2A) . In the MyoDexpressing line D.32, 90% of samples analyzed had density values of 2ϩ and 3ϩ, and line D.37 had 60% of samples with values of 4ϩ. All other ES cell lines that we differentiated had substantially fewer numbers of myocytes ( Fig.  2A) . This increase in myocyte number suggests the possibility that constitutive expression of MyoD in the absence of myogenin efficiently converted naïve cells to the myogenic lineage but also that, without myogenin, most of these cells were unable to fully differentiate into skeletal muscle sheets. However, a conclusive demonstration that forced expression of MyoD led to the recruitment of additional myoblasts awaits a precise comparison of the number of myoblasts in MyoDexpressing and MyoD-nonexpressing lines.
We confirmed that forced expression of MyoD increased the number of myocytes using immunohistochemical detection of MyoD in differentiated embryoid bodies. In wild-type embryoid bodies, MyoD was found mostly in the nuclei of single cells (Fig. 5A) , and little expression was found in myotubes ( Fig. 5B) , indicating that its expression decreased following muscle differentiation. MyoD was abundantly expressed, and a greater number of MyoDpositive nuclei were found in single cells of the two MyoD-expressing lines (Fig. 5C) . These results offer a dramatic example of the inability of MyoD to promote muscle differentiation in the absence of myogenin. Although large amounts of MyoD were expressed in the nuclei of these cells, they were nevertheless unable to fuse and form muscle sheets (Fig. 5C) .
The two MyoD-expressing myogenin (Ϫ/Ϫ) ES cell lines expressed high levels of MyoD transcript, as determined by competitive RT-PCR. Thus, one line expressed 4 times more MyoD transcript compared with wild-type levels, while the other line expressed 29 times more (Table 2) . Although abundant MyoD levels were found in these cells, they were unable to make significant amounts of muscle sheets without myogenin.
The Formation of Muscle Sheets Correlates with myogenin Transcript Expression but Not with the Other Myogenic bHLH Regulators
Using qualitative RT-PCR, we determined which myogenic bHLH factors correlated with muscle sheet formation in differentiating ES cells. We used wild-type, myogenin (ϩ/Ϫ), myogenin (Ϫ/Ϫ), constitutively expressing myogenin, and constitutively expressing MyoD ES cells to detect the expression of MyoD, myf5, MRF4, and myogenin. We invariably observed muscle sheet formation when myogenin transcripts were expressed (Fig. 6, lanes 1, 2, 3, 7, and 8 ). Conversely, we never observed efficient muscle sheet formation when we did not detect myogenin transcripts (Fig. 6, lanes 4, 5, 6, 9, and 10) . In contrast, myf5 and MRF4 expression was detected in myogenin (Ϫ/Ϫ) ES cells and in MyoD-expressing myogenin (Ϫ/Ϫ) ES cells (Fig. 6, lanes 4 , 5, 6, and 10), although these cells were ineffective in making muscle sheets. Although the RT-PCR results were qualitative, they provided further evidence that myogenin has distinct functions that cannot be replaced by the other myogenic factors.
DISCUSSION
Myogenin versus MyoD
The differentiation properties of myogenin (Ϫ/Ϫ) ES cells have allowed us to define an important functional role for myogenin in skeletal muscle formation that cannot be replaced by MyoD. Despite being expressed under identical conditions, MyoD was unable to promote muscle sheet formation in myogenin (Ϫ/Ϫ) ES cells. Throughout this report, we have used the term muscle sheets as an operational definition to indicate extensive skeletal muscle differentiation. However, further analysis would be required to fully characterize the myofiber properties associated with these muscle sheets in differentiating embryoid bodies.
Because the myogenic cDNAs were expressed under the constitutive regulation of the EMSV promoter, the observed differences between myogenin and MyoD are not likely to be explained by differences in temporal expression. Moreover, cell types are highly intermingled in differentiated embryoid bodies, implying that myogenin can function efficiently in the absence of spatially organized progenitor cells. However, EMSV-driven MyoD did not result in MyoD expression in all ES cells at 27 days of culture and it is formally possible that the two myogenic factors were expressed in subpopulations with different morphological capabilities.
Although previous investigations indicated that MyoD and myogenin performed different roles in myogenesis (commitment versus differentiation), these earlier studies did not determine whether the different roles were due to differences in protein sequence or regulation of gene expression (reviewed in Arnold and Braun, 2000) . Our experiments provide strong evidence that myogenin and MyoD behave differently in muscle sheet formation and that, without myogenin, MyoD cannot promote the robust myocyte fusion processes necessary for extensive skeletal muscle differentiation. Thus, myogenin is likely to have functional domains that promote muscle sheet formation that are lacking in MyoD. The results presented here complement those of Gerber et al. (1997) , who showed that MyoD has chromatin remodeling domains within its sequence that are not present within myogenin. Both MyoD and myogenin harbor transcriptional activation domains, but these do not share any discernable similarities (Weintraub et al., 1991; Schwarz et al., 1992; Finkel et al., 1993; Gerber et al., 1997) . Although our analysis has not identified a muscle sheet-promoting domain within the myogenin sequence per se, our expectation is that such a domain exists and would be able to enhance transcription at E-box-containing enhancers in conjunction with the E family of bHLH proteins. E proteins dimerize with the myogenic bHLH factors to greatly enhance DNA binding and transcriptional activation of muscle-specific genes (Blackwell and Weintraub, 1990; Finkel et al., 1993) . In addition, MEF2 proteins cooperate with the myogenic bHLH factors to stimulate transcription at E-box or MEF2 sites (Molkentin and Olson, 1996) . Myogenin-E protein-MEF2 complexes may act more efficiently as transcriptional activators at DNA regulatory elements of muscle genes that act late in the myogenic pathway than the corresponding MyoD complexes, which would be predicted to act selectively on early myogenic genes. It is also conceivable that transcriptional repression or signaling pathways act selectively on myogenin or MyoD (Lu et al., 2000) .
ES cells lacking myogenin produced myosin-positive myocytes and myotubes as efficiently as did wild-type ES cells. We are not sure why myogenin was required for the formation of muscle sheets but was not essential for other aspects of myogenesis. The process of cell fusion appears to be particularly sensitive to myogenin's absence in differentiating ES cells and in vivo. myogenin (Ϫ/Ϫ) myoblasts fuse efficiently in genetic chimeras and in isolated culture, indicating that myogenin may control genes that are critical for producing a fusion-promoting extracellular environment (Nabeshima et al., 1993; Rawls et al., 1995; Myer et al., 1997) . For activation, these genes may require the specific features of myogenin that are not included within the MyoD sequence.
Functional versus Regulatory Differences among the Myogenic bHLH Factors
Although a simple model in which MyoD and myogenin have distinct sequences that are dedicated to either commitment or differentiation is appealing, the relationship among the myogenic bHLH factors and their role in myogenesis is far more complex. MyoD has genetically redundant functions both in myoblast commitment and in differentiation, as evidenced by the phenotype of MyoD (Ϫ/Ϫ): myf5 (Ϫ/Ϫ) or MyoD (Ϫ/Ϫ):MRF4 (Ϫ/Ϫ) double-knockout mice (Rudnicki et al., 1993; Rawls et al., 1998) . MyoD:myf5 double-knockout mice fail to form myoblasts and thus form no skeletal muscle. In contrast, in MyoD:MRF4 doubleknockout mice, myoblasts form and migrate to their appropriate location, but as in myogenin (Ϫ/Ϫ) mice, most of the myoblasts do not fuse to form skeletal muscle. Tripleknockout mice lacking myogenin, MyoD, and MRF4 have more severe muscle deficiencies than myogenin (Ϫ/Ϫ) mice or MyoD (Ϫ/Ϫ):MRF4 (Ϫ/Ϫ) double-knockout mice. Myoblasts are present but even fewer myofibers form in the triple knockout, suggesting that the redundant functions of MyoD and MRF4 in muscle differentiation do not overlap with the functions of myogenin (Valdez et al., 2000) . The genetic redundancies among the myogenic factors make mammalian skeletal muscle formation a robust differentiation system. The phenotypes of the compound mutant mice suggest that a dynamic genetic regulatory network exists among the myogenic bHLH factors in which positive and negative feedback loops and compensatory fail-safe mechanisms ensure the orderly progression of the myogenic differentiation program. Within and downstream of this genetic network, each myogenic factor is likely to control a distinct set of muscle genes based on its specialized function and regulated expression.
Although our analysis emphasized individual functional distinctions between MyoD and myogenin, transcriptional regulation of myogenic factor gene expression also plays an important role. Each factor must be expressed in a distinct temporal, spatial, and quantitative pattern for it to function appropriately. In support of this is the fact that when expressed prematurely or at levels only slightly below those present in myogenin (ϩ/Ϫ) mice, myogenin cannot function effectively (Wang et al., 1996; Vivian et al., 1999) .
myogenin (Ϫ/Ϫ) ES cells should be particularly useful in identifying functional domains that impart muscle sheetforming capabilities to myogenin. By creating protein chimeras between MyoD and myogenin, it should be possible to determine whether sequences present on myogenin can replace corresponding sequences on MyoD and lead to muscle sheet formation in differentiating myogenin (Ϫ/Ϫ) ES cells.
